Levi & Korsinsky announces it has commenced an investigation of Flex Pharma, Inc. (“Flex Pharma” or “the Company”) (NASDAQGM: FLKS) concerning possible violations of federal securities laws. On June 13, 2018, Flex Pharma announced it would cease its “ongoing Phase 2 clinical trial investigations of FLX-787 in amyotrphic lateral sclerosis and Charcot-Marie-Tooth due to oral tolerability concerns observed in a subset of patients…” The Company also announced a restructuring plan that includes reducing its workforce by approximately 60 percent. Following this news, shares of Flex Pharma fell from a close of $4.18 per share on June 12, 2018, to a close of $1.04 per share on June 13, 2018. To obtain additional information on the Flex Pharma class action investigation (FLKS class action investigation), go to: http://www.zlk.com/pslra-d/flex-pharma-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.